The purpose of this study was to evaluate the safety, pharmacokinetics (PK) and preliminary
efficacy of multiple ascending intravenous doses of 3K3A-APC, a Recombinant Variant of Human
activated protein C (APC), in in the treatment of acute ischemic stroke following treatment
with recombinant tissue plasminogen activator (tPA), mechanical thrombectomy or both.
Phase:
Phase 2
Details
Lead Sponsor:
ZZ Biotech, LLC
Collaborators:
Cedars-Sinai Medical Center Massachusetts General Hospital National Institute of Neurological Disorders and Stroke (NINDS) University of Iowa